Try our Advanced Search for more refined results
Life Sciences - January, 2018
373 articles
- Teikoku Swears Off Pay-For-Delay In Lidoderm Deal With AGs
- Renal Clinics Will Pay $4M To Settle Investors' Fraud Claims
- J&J Baby Powder Contained Asbestos, Expert Tells Jury
- Axing Restasis Patents Would Stifle Innovation, PhRMA Warns
- Danish Watchdog Says CD Pharma Abused Its Dominance
- Patent Owners Should Think Hard Before Giving Up At PTAB
- Shkreli Sentencing Delayed While Parties Mull Loss, Forfeiture
- Investors Blast NuVasive's Sanctions Bid Over Depositions
- FTC Looks To Beat Suit Challenging Its Authority
- GAO Blocks Big Biz Protest On FDA Small Biz Software Deal
- Pharmacist Gets 8 Years For Making Meningitis-Linked Drugs
- AbbVie Seeks New Trial After $140M AndroGel Verdict
- Daiichi Wins Enforcement Of $550M Ranbaxy Award In India
- Life Sciences Group Of The Year: King & Spalding
- Centers Of Influence Are Key To Small Law Firm Rainmaking
- NH Asks Justices To Deny Endo's Challenge Of Outside Atty
- Ensuring Section 121 Safe Harbor Applies To Patent
- Medtronic Investors Win Cert. In Revived Stock-Drop Suit
- Life Tech Rips Promega Bid To Rethink US Damages In IP Row
- Fed. Circ. Says PTAB Erred In Axing Part Of Surgical Patent
- Aegerion Sentenced To Pay Patients In Twist On $36M Plea
- Mass. AG's Medicaid Fraud Dept. Got $45M Back In 2017
- FDA Warning Wire: Drugmaker Misled Customers About Tests
- Consumers Urge 9th Circ. To Revive Costco Labeling Suit
- Meet The Judge Who's Steering The Epic Opioid MDL
- No Asbestos In J&J Talc, NJ Jury Told In Mesothelioma Case
- Ex-Teva Exec Didn't Violate CFAA In Sharing Info With Lover
- Struggling Teva Pharmaceutical Plans To Raise $5B In Debt
- Life Sciences Group Of The Year: Williams & Connolly
- Accutane Suits Filed Too Late, NJ Panel Affirms
- Pfizer Expects $15B Tax Bill For Overseas Assets
- Akorn, Fera, Perrigo Settle Trade Secrets, Antitrust Suit
- Cymbalta Users Try To Revive Case After High Court Setback
- Irish Medical Device Co. Pockets €40M In Funding Round
- TC Heartland And Hatch-Waxman: Square Peg In Round Hole
- The Future Of France Is Innovation
- Trial Over J&J Talc, Mesothelioma Link Kicks Off In NJ
- Investors Seek Early OK For $290M Valeant, Pershing Deals
- New DOJ Memo Will Make Waves In Fraud Cases
- Forest Beats Final Cases In Celexa, Lexapro MDL
- Patent Deal Clears Actavis' Zohydro Generic For 2029
- Pharmacist Should Pay Meningitis Victims $82M, Gov't Says
- 6 More Cos. Launch IPOs Totaling $1.4B As Pipeline Grows
- Kite Pharma Investors Seek Appraisal After $11B Gilead Buy
- From Law Firm To Newsroom: An Interview With Bob Woodruff
- Ex-Dentist Cops To $16.6M Medical Device Fraud
- Health-Focused VC Firm Rebrands, Launches $100M Fund
- EU Extends Deadline For Bayer-Monsanto Review
- Novartis Blasts Attempt To Revive Pay-For-Delay Suit
- Life Sciences Group Of The Year: Paul Hastings
- Sanofi Beats Novo To Buy Ablynx For $4.8B
- Judging A Book: Kendall Reviews 'On The Jury Trial'
- Gene-Edited Crops Ripe For Renewed Regulatory Focus
- What's At Play In First J&J Talc Asbestos Trial
- High Court Denies Helsinn's Bid To Stay On-Sale Bar Ruling
- Equistone Sells Off Life Sciences Co. In £163M Deal
- Kimberly-Clark, Others To Pay $3.9M In Bay Pollution Spat
- Ixchel On Last Legs With Antitrust Claims Against Biogen
- Mylan Pradaxa Generic Delayed In Boehringer Patent Deal
- New Orleans Doc Gets 10 Years For Running Opioid 'Pill Mill'
- Don't Miss It: Hot Deals & Firms We're Following This Week
- AbbVie Drug Did Not Cause Man's Blood Clots, Jury Finds
- How Cos. Can Take Advantage Of DOJ False Claims Act Memo
- FDA Must Explain Amgen Exclusivity Denial, Judge Rules
- Health Hires: Frost Brown, EBG, McDermott, Dykema Cox
- Life Sciences Group Of The Year: Fish & Richardson
- Cannabis Co.'s Tribal-Land Op Suit Moved To State Court
- 7 Cos. To Price IPOs Exceeding $3.4B Led By Gaming REIT
- Takeda, Lilly Escape Already-Settled Diabetes Drug Claims
- Taxation With Representation: Weil, Proskauer, Debevoise
- CBRE Director Sees 'Frantic Rush' As Biotech Space Evolves
- FCA Memo No Proof Of New DOJ Direction On Dismissals
- FDA Lawfully Denied Exclusivity For Namenda Generic: Judge
- Medicis Falls Short In Bid To Escape Pay-For-Delay Suit
- LivaNova Wants Consolidation Of Bacteria Exposure Suits
- Allergan, Restasis Buyers Can't Agree On MDL Venue
- Shareholders Sue Cancer-Drug Maker Over $1.7B Roche Deal
- Lyondell Trustee Can't Recover $300M Payment To PE Mogul
- Greenberg Traurig Adds Deals Pro From Mitchell Silberberg
- PE-Backed Gates Industrial Leads 3 IPOs Raising $878M
- Attys React To DOJ's New Memo On FCA Dismissals
- Real Estate Rumors: Fortis, Blackstone, Soon-Shiong
- Patients Seek Calif. MDL In Suits Over Diabetes Drugs
- Asacol Antitrust Trial Delayed To Let Allergan Appeal Class
- Do I Need New Trial Counsel? 9 Questions To Ask
- Forest Beats Bid For More Docs In Celexa, Lexapro MDL
- Illumina Wins $27M Prenatal Test IP Verdict Against Ariosa
- Cooley Leads Pot PE Fund To Close $100M Series C Round
- Groups Warn Against NAFTA Changes That Raise Drug Prices
- A Look At Chemical Supplemental Examination Requests
- Feds Push To Expand FCA Billing Suit Against Fresenius
- Express Scripts Escapes Shareholder Class Action
- FDA, Endo Freeze High-Stakes Drug Compounding Case
- Deals Rumor Mill: Weinstein Co., Luye, Microsemi
- Medical Device Co. To Pay $7.6M In Electrode FCA Suit
- Mass.' New US Atty Keeps Heat On Pharma Donations
- Grocers Slam Teva, Mylan Over Drug Price-Fixing 'Conspiracy'
- ABA, INTA Urge Full Fed. Circ. To Kill USPTO Fee Rule
- Fed. Circ. Upholds PTAB Ruling In Suture Patent Case
- Shire Rips Allergan's 'Stranglehold' On Dry-Eye Drug Market
- Rite Aid Customers Sue Over Excessive Generic Rx Copays
- FDA, FTC Target Opioid Addiction Treatment Claims
- 10 Antitrust Developments And Trends To Watch In 2018
- Allergan Vies For Insurance Coverage Lists In Asacol Trial
- Senate Confirms Eli Lilly, Wiley Rein Vet To Lead HHS
- Bodybuilding Co. Says Steroid-Alternative Suit Lacks Detail
- Aurora Cannabis' $890M CanniMed Deal Ends Takeover Fight
- Rite Aid To Pay $4M Over Improper Meth Ingredient Sales
- Illumina, Ariosa Seek Tens Of Millions As IP Trial Ends
- Aetna To Pay $1.15M To New Yorkers Hit By HIV Info Breach
- 1st Circ. 'Reluctantly' Nixes Sanctions In $70M Fine Appeal
- Texas Fracker Leads 3 Cos. Launching IPOs Totaling $440M
- DLA Piper Adds 2 Partners To Chicago Office
- EU Court Backs €183M Fine In Italian Drug Antitrust Case
- Revere Sues Pharma Cos. Over Opioids, Boston Might Follow
- Fed. Circ. Backs PTAB's Invalidation Of J&J Remicade Patent
- Medline Says TC Heartland Doesn't Apply To Bard Transfer Bid
- Pharma Can't Be Liable For Generics, GSK Tells 7th Circ.
- Israeli Info Crucial To $163M Perrigo Tax Row, IRS Says
- Omnicare Settles DOJ's Citizenship Discrimination Probe
- FDA Warning Wire: Web Sales Of Banned Obesity Drug
- NYC Sues Drugmakers, Distributors Over Opioid Epidemic
- Health Care, Life Sciences M&A To Stay Strong In 2018
- Lessons From President Trump's Failed Judicial Nominations
- J&J Hit With $13.6B Charge Under New Tax Law
- Video-Averse Plaintiffs' Atty Has Been Abusive, Puma Says
- Zydus Gets FCA Claims Trimmed In Generics Pricing Row
- Patient Info Not A Kickback, MedImmune Says In Fraud Suit
- High Court Considers Upending Patent Damages
- IP Owners Group Says USPTO Fees Rule Is 'Crippling'
- Fed. Circ. Bats Down Helsinn Bid To Stay On-Sale Bar Ruling
- Fenwick IP Partner Tapped As Calif. Fed. Magistrate Judge
- Express Scripts Beats Pharmacy's Antitrust Suit
- FDA Faces $50M Suit After Discrediting Drug Research Co.
- Cherokee Nation Takes Opioid Claims To Okla. State Court
- Attorneys Squabble Over Cut Of $785M Pfizer FCA Deal
- UPDATED: Medtech Startup Drops Suit Against Would-Be CEO
- Justices Asked To Weigh Patentability Of Natural Processes
- Whole Foods Overloads Supplements With B12, Suit Says
- German Surgical Toolmaker Cut From NJ Cancer Death Suit
- 11th Circ. Upholds Amgen, Pfizer Win In Infection Suit
- Lab Owner Never Agreed To Be Face Of Sex Drug, Suit Says
- How To Control Data As Technology Complicates E-Discovery
- Clashing Marijuana Laws Create Insurer Anxiety
- Celgene Continues Active January With $9B Juno Acquisition
- Sanofi Buys Hemophilia Drugmaker In $11.6B Deal
- Immigration Standoff Keeps Government Shuttered
- Lab's Peptide IP Suit May Run Aground On Safe Harbor
- '#Killinnazis' Uproar Shows Attys Must Tread Lightly Online
- Del. Becomes Latest To Sue Pharmas Over Opioid Crisis
- 7th Circ. Won't Revive Claims Of 1,000 Pfizer Suits In MDL
- Fed. Circ. OKs Gilstrap Erasing Jury's Invalidity Verdict
- 9 IPOs Projected To Exceed $3B In Year's Busiest Week
- Abbott, Plaintiffs Seek Stay Of Depakote Suits, Pending Talks
- Cornell, Life Tech Must Arbitrate IP Settlement Fight
- Merck Loses Bid To Revive Antibiotic Patent In Fed. Circ.
- Helsinn Wants On-Sale Bar Ruling Held For High Court Appeal
- 2017 Health Care Enforcement Review: Final Thoughts
- Fed. Circ. Presens Ruling Provides Insights On Prior Art
- GSK Says Families Too Late To Amend Zofran MDL
- Janssen Sues Teva To Stop Generic Of Schizophrenia Drug
- Prosecutor Flustered By Surprise Motions At Insys Hearing
- Generics Co. Resists Allergan's Bid To Leave Restasis IPRs
- 4 Key Takeaways From FDA's 2017 Enforcement Stats
- House OKs Spending Bill To Head Off Gov't Shutdown
- Fake Medical Pot Certifications Get Fla. Atty Disbarred
- 9th Circ. Urged To Revive Prostate Supplement Labeling Row
- 3 Antitrust Cases Drug Companies Should Watch This Year
- 2017 Health Care Enforcement Review: Materiality Under FCA
- Argentum Wins Invalidation of J&J Unit's Cancer Drug Patent
- Deals Rumor Mill: CBS, J&J, Weinstein Co.
- Merck, Glenmark Stifled Cholesterol Drug Market, Suit Says
- AndroGel Can Cause Blood Clots Many Ways, Doc Tells Jury
- Investor Gets 1 Year For Insider Trading On Gilead Buy
- Calif. County Wants Tribe's Suit Over Hemp Seizure Nixed
- IRS Delays Penalty For Excise Tax On Medical Devices
- Chamber Backs GSK In 3rd Circ. Flonase Rehearing Bid
- Puma Biotech Investors Say Depo Camera Is Meant To Harass
- Pa. Court Urged To Resurrect Actiq Off-Label Marketing Suit
- House May Vote On Spending Bill Delaying ACA Taxes
- J&J Unit Can't Nix FCA Suit Over Hip Implants Yet
- Ex-Sen. Dodd, Eli Lilly Litigation Head Join Arnold & Porter
- Hep C Meds Patent Row Can't Stay In Minn., Fed. Circ. Says
- Ex-Aveo Exec Says SEC Exaggerated Role In Investor Fraud
- Philly Becomes Latest To Sue Drugmakers For Opioid Crisis
- Drugmaker Urges Full Fed. Circ. To Kill USPTO Fee Rule
- Removal In 2017: How Defendants Got To Federal Court
- 2017 Health Care Enforcement Review: FCA Case Law
- A Chat With Davis Wright CSO Mark Usellis
- Fed. Circ. Clarifies But Won't Redo AIA On-Sale Bar Ruling
- FDA Warning Wire: Allergan Gets New Ammo Against Rival
- NJ Lab Sues Horizon Over Coverage For Women On Medicaid
- Smith Stratton Joins Dilworth Paxson In Like-Minded Merger
- Allergan Deal Clears 2031 Launch Of Sun's Linzess Generic
- Purdue's 'Duplicative' Suit Over OxyContin Generic Gets Ax
- America's Shifting Views On Marijuana Post-Cole Memo
- 5 Cos. Launch IPOs Surpassing $1B As January Gains Steam
- Insurers Accused Of Blocking Allergy Testing Competition
- NJ Opioid Laws Tackle Rx Fraud, Nix Antidote Liability
- High Court Won't Consider Atty Fees In Medtronic Case
- 2017 Health Care Enforcement Review: Trends In FCA Cases
- A Definiteness Reminder For Pharmaceutical Patent Drafters
- A Momentous Year For CFIUS: Part 2
- The Firms That Dominated In 2017
- Law360 Names Practice Groups Of The Year
- 1st Circ. Sends 3 More Meningitis Pharmacists To Trial
- Valeant Says Insurers Must Defend Allergan, Stock-Drop Suits
- Valeant Sees Most Claims Against It Stick In Stock-Drop Suits
- Tribe Says Immunity Unscathed By Joining Allergan IP Suit
- Pfizer's Hospira Billed Gov't For Faulty Pumps, Suit Says
- 3 Firms To Steer IPOs Totaling $2.5B As Deal-Making Resumes
- PTAB To Review Tyvaso Patents Despite Time-Bar Protest
- Drug, Device Makers Cheer As FDA Punts Off-Label Policy
- Investors Want Abbott To Explain Delay In Alere Deal
- Shkreli Hits Back At Feds' $7.3M Forfeiture Bid
- Atty's Malpractice Jurisdiction Fight Dies At Texas High Court
- Ex-Insys Manager's Opioid Kickback Trial Pushed To Sept.
- Balancing Vertical Integration In Calif.'s Cannabis Industry
- Justices To Hear Chinese Vitamin C Price-Fixing Case
- A Survey Of In-House Attorney Views On Trade Secrets
- A Momentous Year For CFIUS: Part 1
- Applying BMS To Federal Class Actions: Due Process Matters
- NJ's Evolving Health Care Arena: Trends To Watch In 2018
- DOJ Ups Estimate Of FCA Whistleblower Recoveries
- Teva Investors Fight Bid To Nix Price-Fixing Suit
- Restasis Is FDA-Approved, Allergan Reminds Compounder
- 1st Circ. Chides Biolitec For Umpteenth Appeal Of $70M Fine
- Dr. Scholl's Shoe Inserts Aren't Custom Fit, 2nd Circ. Told
- Opioid Addiction Treatment Co. Nabs $110M For New Product
- Fla. Compounding Pharmacy, Execs Escape Rep's FCA Claims
- US Blasts Raytheon Escape Bid In Mass. Cleanup Liability
- Amgen, Genentech Await Del. Ruling In Biosimilar IP Row
- DQ King & Spalding In Vaccine Patent Row, Ex-Client Says
- Novartis' Zortress Patent Survives PTAB Challenge
- 6 E-Discovery Predictions For 2018
- Murky FDA Device Guidance Kills Sanofi Antitrust Suit
- Endo Hit With Subpoena For Opioid-Related Docs
- The Latest Fed. Circ. Approach To 'Inference Of Intent'
- What I Learned In My 1st Year: Read The Whole Thing
- Pharma Charity's Suit Tests OIG's Kickback Oversight
- Allergan's Restasis Patents Are Valid, Fed. Circ. Told
- Yale Doc Fights To Keep Fees After Beating Defamation Suit
- Former Sedgwick Partner Lands At Porzio Bromberg
- Saul Ewing Adds Ex-Sedgwick Partners In Miami, New York
- No Quick Road Ahead For Pa. Risperdal Punitives, Attys Say
- BakerHostetler Grows Corporate Practice With Stradling Hire
- No Tribal Jurisdiction In Cherokee Opioid Suit, Judge Says
- Supplement Co., FTC Settle Cancer Treatment Product Suit
- Settlement Aspirations Enter The Opioid MDL
- Bayer, Merck Want Suit Questioning Coppertone SPF Tossed
- Simmons Nabs Ex-CMS London Atty For New Patent Group
- Law360's Pay-For-Delay Case Cheat Sheet For 2018
- 3-D Printed Implants Pose Challenge For Product Regulators
- 6 Roles To Embrace In An Evolving Legal Industry
- Ariosa, Illumina Spar Over Patent Timing In DNA Test Trial
- Baupost Hit With $4M Short-Swing Suit Over Innoviva Stock
- Allergan Wants Out Of Restasis Patent Challenges
- Perrigo Fights Deposition Of Dexcel Workers In $163M Bout
- Deals Rumor Mill: Siemens, Akamai, GSK
- Apotex Gets PTAB To Trim OSI's Cancer Drug Patent
- Mass. US Atty Won't Rule Out Pot Prosecutions Post-Reversal
- Pa. Judge Junks $28M Xarelto Verdict Against J&J, Bayer
- HHS Nominee Eyes New Tacks On Drug Prices, Provider Pay
- FTC Lawyers Slam LabMD's Retaliation Suit In DC Circ.
- Aggrenox End-Payors Reach $54M Deal In Pay-For-Delay Suit
- Will Life Sciences Companies Face More Scrutiny In 2018?
- Cannabis Co. Hits Back At Tribal Corp.'s Dismissal Bid
- SD Tribes Add To Flood Of Opioid Marketing Suits
- Hagens Berman, Others Want $31M In Pfizer Celebrex Deal
- Judge Urges Speedy Pace For Opioid MDL Amid Crisis
- This Year, Let's Invest In Lawyer Resiliency
- Amici Views On Big Pharma 'Renting' Sovereign Immunity
- High Court Declines To Review 7 IP Cases
- Genomics IP Trial Between Illumina And Ariosa Kicks Off
- Docs Weren't Warned About AndroGel's Risks, Jury Told
- Endo Gets OK To Join FTC's Impax Pay-For-Delay Case
- Allergan Fights To Keep Live Testimony In Asacol Trial
- Doc's Attys Duel Over Fee Split In $785M Pfizer FCA Deal
- Supreme Court Declines To Rehash Stryker Noncompete Win
- GSK Wants 3rd Circ. To Rehear La. Flonase Decision
- Seattle Genetics Mounts 3rd Bid To Defeat Stock Fraud Suit
- CSL Must Face Shire's Willful Infringement Claim
- 5 Legal Technology Predictions For 2018
- Deals Rumor Mill: Dermapharm, Aramco, Life Healthcare
- OFAC Enforcement Trends In 2017: Exporters On Notice
- J&J May Face Punitive Damages In Pa. Risperdal Cases
- Restasis Antitrust Suits Paused For MDL Panel Review
- Womble Bond Adds Ex-Taylor English Patent Pro In Atlanta
- Belgian Biotech Ablynx Pushes Aside $3.1B Novo Nordisk Bid
- Indirect Purchaser Cases In 2017: Key District Court Rulings
- 3 Enforcement Priorities For State AGs In 2018
- Why Physician Choice Matters In Medical Product Cases
- AbbVie Faces Third Jury In Testosterone MDL
- PTAB Scolds Tribe Over Unauthorized Impartiality Motion
- Covidien Nears OK For Stay Of California IP Suit
- VC-Backed Israeli Biopharma Co. Launches $55M IPO
- OIG Allows Free Drugs After Axing Charity's Kickback Shield
- Ex-ArthroCare Exec Gets 4 Years In $750M False Sales Plot
- Thermo Fisher, Phadia To Exit Allergy Test Antitrust Suit
- Lawyers Head To JPMorgan Conference Eager To Spark Deals
- NC Cherokee Tribe Latest To File Opioid Marketing Suit
- Judge Sticks By Approval Of $350M Shire FCA Deal Split
- Valeant Hit With Investment Funds' Fraud Scheme Suit In NY
- NJ Biotech Co. Closes $76M Financing Round
- Health Hires: DEA, Womble Bond, LeClairRyan Bulk Up In DC
- Allergan Target Faces Bid To Halt Vote On $30M Merger
- DLA Piper Guides Takeda In €520M Biopharma Acquisition
- Jury Misconduct Claimed In Ex-Katten Atty Trial
- Atty In $28M Xarelto Trial Could Be Nixed Over Judge Photo
- NY Surgical Instruments Co. Hit With Junk-Fax Claims
- Court Divide Could Spur More Hatch-Waxman Venue Fights
- A Look At Recent Efforts To Contain Health Care Costs
- Top 4 Health Care Cybersecurity Threats For 2018
- Gilead Takes Key FCA Battle To Supreme Court
- The Broader Implications Of Sessions' Marijuana Move
- Pharma Distribution Group Says Antitrust Suit Is Nonsense
- FDA Warning On Stem Cell Co. Keeps Up Heat On Industry
- More Relators Push FCA Cases To The End In 2017
- Transposagen Can't Use TC Heartland To Nix Antibody IP Suit
- Lead Attys Named For Massive Opioid MDL
- TerraVia Holdings Moves Ahead With Ch. 11 Liquidation
- Allergan Announces Reduction Of 1,000 Jobs
- Sessions' Reversal Likely To Kill Any Pot Buzz For Banks
- Fed. Circ. Revives Infringement Row Over Pill Coating
- Sessions Reverses Obama-Era Marijuana Enforcement Policy
- Celgene Hits Supplier With Cancer Drug Trademark Suit
- Janssen Gets $5.6M Verdict Tossed In Calif. Appeals Court
- 3rd Circ. Affirms CSL's Win In Employee Retaliation Suit
- 9th Circ. Won't Rethink Costco's Win In Apotex Origin Case
- Roche Maintains Suppliers Broke Test-Strips Contract First
- Pa. Marijuana Investors Cut Out License Preparer, Suit Says
- Litigation Finance Trends To Watch In 2018
- 5 Health Care Policy Issues To Follow In 2018
- Why Sales Rep Witness Tampering Accusations Matter
- Shire, Ultragenyx Settle Row Over 'Trade Secret' Doctor List
- Omnicare Deemed Joint Employer In Drivers' Wage Suit
- Mass. Gynecologist Loses Bid For Grand Jury Instructions
- Aviragen Stockholder Sues For Meeting Before $60M Merger
- Generics Buyers Fight To Keep 2 Drugs In Antitrust MDL
- 3rd Circ. Backs Nix Of Pharmacies' Claim In Lipitor MDL
- Mohawk Tribe Demands Info On 'Impartiality' Of PTAB Judges
- DNA Data Co. Gets $58M From Google, Microsoft, VC Firms
- Pot Exec Says Atty's Arbitration Pact Doesn't Apply To Him
- LeClairRyan Sued For Malpractice By Ex-Blood Test Exec
- Drug Buyers Can't Get Forest Labs Docs Related To Probe
- Judge Sets Busy Trial Slate For Philly Testosterone Cases
- FDA Unveils Guidance To Smooth Generic-Drug Path
- The Enneagram And The Practice Of Law
- Shook Hardy Brings On Ex-Sedgwick Chair
- Alissa Starzak On Net Neutrality, US Army, Leap To Startup
- Amgen Says It Didn't Mislead On Biosimilar Marketing Date
- Chinese Medical Marketplace Closes $60M Funding Round
- FDA Issues Highest-Level Recall For J&J Heart Device
- Funds Say Valeant Price-Gouging Probe Cost Them $80B
- Pershing, Valeant Agree To $290M Deal Ending Allergan Suits
- Ex-Katten Atty Conviction A Cautionary BigLaw Tale
- Sloan Kettering Gets Trimmed Fees In IP Fight
- Biotech Cos. Lead 7 Post-Christmas IPO Filings
- Lupin, Sandoz Settle With Retailers In Solodyn Suit
- FDA Warning Wire: Diet Drug Deceit, Fresenius Failings
- Auxilium Settles 1st Philly Testosterone Case
- Massachusetts Marijuana Regulatory Scheme Takes Shape
- Judging A Book: Tymkovich Reviews 'Gorsuch'
- Pear Therapeutics Closes Temasek-Led $50M Funding Round
- Bristol-Myers, Consumers Look To Centralize NJ Abilify Suits
- The Hottest Patent Law Issues Of 2017
- Key New Jersey Cases To Watch In 2018
- Life Sciences Regulation To Watch In 2018
- Illinois Cases To Watch In 2018
- Life Sciences Cases To Watch In 2018
- California Cases To Watch In 2018
- Patent Cases To Watch In 2018
- 5 Things To Watch For In FCPA Enforcement This Year